Preimushchestva svoevremennoy initsiatsii insulinoterapii. Rezul'taty rossiyskoy observatsionnoy programmy HUBIN
- Authors: Chernikova N.A1, Ivanova L.P1, Abaeva F.T1
-
Affiliations:
- Issue: No 5 (2015)
- Pages: 32-37
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287810
- ID: 287810
Cite item
Open Access
Access granted
Abstract
There is plenty of evidence that the timely start of insulin therapy is necessary for patients with type 2 diabetes mellitus (T2DM). Observational study showed that initiation of insulin therapy in 1500 patients who did not have a target level of glycemic control against on therapy with oral antidiabetic drugs resulted in a statistically significant reduction of glycosylated hemoglobin (HbAic) levels and fasting plasma glucose levels. The target level of HbAic was achieved 42.3% of patients on therapy with Insuman Basal and 29.2% -on therapy with other NPH insulins. In addition, the frequency of hypoglycaemia was minimal: 2 cases of severe hypoglycemia among 1,500 patients.
Full Text
References
- Алгоритмы специализированной медицинской помощи для больных сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой. М., 2013.
- Inzucchi S.E., Bergenstal R.M., Buse J.B., Dia-mant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A, Wender R., Matthews D.R. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-49.
- Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008;359:1577-89.
- Owens D.R. SourceDiabetes Research Group, Institute of Life Sciences College of Medicine, Swansea University, Swansea, United Kingdom. Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. Diabetes Technol. Ther. 2013;15(9):776-85: 10.1089/ dia.2013.0081. Epub 2013 Jun 20.
- Fonseca V., Gill J., Zhou R., Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycae-mic control and hypoglycaemia. Diabetes Obes. Metab. 2011;13(9):814-22.
- Gerstein H C., Yale J.F., Harris S.B., Matthews D.R., Neil H.A. A randomized trial of adding insulin glargine vs. avoidance of insulin in peoplewith Type 2 diabetes on either no oral glucoselower-ing agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet. Med. 2006;23:736-42.
- Holman R.R., Farmer A.J., Davies M.J., Levy J.C., Darbyshire J.L., Keenan J.F., Paul S.K.; 4-TStudy Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N. Engl. J. Med. 2009;361:1736-47.
- Аметов А.С. Сахарный диабет 2 типа. Проблемы и решения. М., 2011. 254-55 с.
- Brown J.B., Nichols G.A., Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-40.
- Litwak L., Goh S.Y., Hussein Z., Malek R., Prusty V., Khamseh M.E. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study. Diabetol. Metab. Syndr. 2013;5(1):57.
Supplementary files
